Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
Active, not recruiting · NCT01623167 · Registry updated 2026-04-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia | Bone Marrow Failure Disorders, Cytopenia, Hemic and Lymphatic Diseases, anemia, aplastic anemia, autoimmune disease, blood platelet disease, bone marrow disorder, hematologic disorder, immune system disorder, pancytopenia, thrombocytopenia | Active, not recruiting | Phase 1 / Phase 2 | 2026-04-13 | NCT01623167 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | 791 |
| Novartis | 114 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | United States | 5 |